Global Healthcare Analyst

Tina Banerjee

Thematic (Sector/Industry)

<ul>
<li>Sino Biopharmaceutical entered outlicensing agreement with Sanofi for rovadicitinib for upfront payment of $135M. Antengene entered outlicensing agreement with UCB for ATG-201 for upfront and near-term milestone payment of $80M.</li>
<li>FDA accepted Takeda’s NDA for polycythemia vera drug rusfertide and granted Priority Review.  Sumitomo Pharma received conditional and time‑limited approval in Japan for the allogeneic cell product Amchepry.</li>
<li>FDA has cleared ABL Bio’s application for a Phase 1 clinical trial of ABL209. Glenmark Pharmaceuticals received FDA approval for generic Flovent with 180-day CGT exclusivity.</li>
</ul>


Sino Biopharmaceutical entered outlicensing agreement with Sanofi for rovadicitinib for upfront payment of $135M. Antengene entered outlicensing agreement with UCB for ATG-201 for upfront and near-term milestone payment of $80M.
FDA accepted Takeda’s NDA for polycythemia vera drug rusfertide and granted Priority Review.  Sumitomo Pharma received conditional and time‑limited approval in Japan for the allogeneic cell product Amchepry.
FDA has cleared ABL Bio’s application for a Phase 1 clinical trial of ABL209. Glenmark Pharmaceuticals received FDA approval for generic Flovent with 180-day CGT exclusivity.


APAC Healthcare Weekly (March 8) – Sino Bio, Antengene, Takeda, Sumitomo Pharma, ABL Bio, Glenmark

Asia and Global Semiconductor and Tech Research

Andrew Lu

Equity Bottom-Up

Taigen Biopharmaceuticals / Equity Bottom-Up

<h2>Summary</h2><ul>
<li>
<strong>What's new? </strong>Taigen and HEC Pharm announced a new joint venture.  HEC Pharm agrees Taigen to use its developed new drug Furaprevir (TG-2349) at RMB$335mn or NT$1.56bn investment value to take 49% of the new company.</li>
<li>
<strong>What is Furaprevir? </strong>On August 18, 2016, Taigen received a clinical trial authorization for Class 1.1 new drug from China Food and Drug Administration (CFDA) for Furaprevir. Furaprevir is an investigational HCV NS3 protease inhibitor discovered and developed by TaiGen for the…</li>
</ul>

Summary

What's new? Taigen and HEC Pharm announced a new joint venture.  HEC Pharm agrees Taigen to use its developed new drug Furaprevir (TG-2349) at RMB$335mn or NT$1.56bn investment value to take 49% of the new company.

What is Furaprevir? On August 18, 2016, Taigen received a clinical trial authorization for Class 1.1 new drug from China Food and Drug Administration (CFDA) for Furaprevir. Furaprevir is an investigational HCV NS3 protease inhibitor discovered and developed by TaiGen for the…


TaiGen Sold Its Furaprevir for 25x of Market Capital

Taiwan

TaiGen Biopharmaceuticals Holdings Limited is a research-based pharmaceutical company engaging in the development of novel therapeutics for infectious diseases, cancer research and diabetes-related complications.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Taigen Biopharmaceuticals (4157 TT)

APAC Healthcare Weekly (March 8) – Sino Bio, Antengene, Takeda, Sumitomo Pharma, ABL Bio, Glenmark

Sino Bio and Anetengene stuck outlicensing deals with Sanofi and UCB, respectively. FDA accepted Takeda’s NDA for rusfertide. Sumitomo Pharma got...

Tina Banerjee

TaiGen Sold Its Furaprevir for 25x of Market Capital

Summary What's new? Taigen and HEC Pharm announced a new joint venture. HEC Pharm agrees Taigen to use its developed new drug Furaprevir...

Andrew Lu

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)